Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies


Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

AIM Rule 26

The information below is disclosed in accordance with AIM Rule 26 and details are updated on a regular basis:

Business Description

Please see our About page.

Directors Names & Biographies

Information about our directors can be found on our Directors page.

Corporate Governance

Please see our Corporate Governance page.

Main Country of Incorporation and Operations

Country of incorporation: England and Wales
Company registration number: 09761509
Main country of operation: United Kingdom

UK Takeover Code

The Company is subject to the UK City Code on Takeovers and Mergers.

Current constitutional documents such as articles of association and memorandum of association

All relevant documents can be found on our Documents page.

Details of any other exchanges or trading platforms

Please see the Share Price Summary page for details.

The number of aim securities in issue (noting any held as treasury shares)

Securities in issue:
The Company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 216,192,462.


The identity and percentage holdings of significant shareholders

The Company has been notified of the following holdings of 3% or more of the issued share capital of the Company:

Name Holding %
Inventages 56,008,541 25.91
AOP Health International Management AG 28,340,711 13.11
Hargreaves Lansdown, Stockbrokers (EO) 22,190,629 10.26
Interactive Investor (EO) 15,586,547 7.21
Jupiter Asset Management 12,107,995 5.60
AJ Bell, stockbrokers (EO) 11,182,604 5.17
HSDL, stockbrokers (EO) 8,093,661 3.74

In accordance with AIM Rule 26, in so far as the Company is aware as at 8 August 2022, the percentage of the Company’s issued share capital that is not in public hands is 43%.

Details of any restrictions on the transfer of aim securities

There are no restrictions on the transfer of ordinary shares.

Annual and interim financial reports

Please see the Documents page for more information.

Regulatory news

Regulatory news announcements can be found on our RNS News page.

Aim admission document and circulars

All relevant documents can be found on our Documents page.


Please see the Advisor Contacts page for more information.

This content was last updated on 08 Aug 2022.